| 摘要 |
<p>The disclosure relates to prostaglandin analogues of the 2-series in which the 5,6 double bond is in the trans configuration, for example 16-(3-chlorophenoxy)-9.alpha.,11.alpha., 15-trihydroxy-17,18,19,20-tetranor-5-trans,13-trans-prostadienoic acid, to processes for their manufacture, to pharmaceutical and veterinary compositions containing them, and to methods of treatment.</p> |
